Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | AQP1 | P29972 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21436692 | 0.92 | CA2 (0.62) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL11371169 | 0.88 | CA2 (0.68) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL21436410 | 0.87 | CA2 (0.59) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL21454037 | 0.87 | KDM4E (0.61) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL21436856 | 0.86 | CA2 (0.60) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL22922706 | 0.86 | CA2 (0.62) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL11377765 | 0.85 | CA2 (0.69) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL21436548 | 0.85 | CA2 (0.61) | CA2KDM4EUSP2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL28600290 | 0.85 | CA2 (0.61) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL21436432 | 0.85 | CA2 (0.63) | CA2KDM4EUSP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132103-A1 | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs | UNIV OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-05-14 | — | — | US | disclosed |
| CN-112969692-A | Bumetanide derivatives for the treatment of hyperhidrosis | 兹伦汀公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210163406-A1 | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs | Universität Wien (AT) | 2021-06-03 | — | — | US | disclosed |
| US-20210163406-A1 | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs | Universität Wien (AT) | 2021-06-03 | — | — | US | disclosed |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Zilentin AG (CH) | 2021-01-28 | — | — | US | disclosed |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Zilentin AG (CH) | 2021-01-28 | — | — | US | disclosed |
| WO-2019193161-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF STROKE AND OTHER NEUROLOGICAL DISEASES/DISORDERS INVOLVING NKCCS | Universität Wien (AT) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019193161-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF STROKE AND OTHER NEUROLOGICAL DISEASES/DISORDERS INVOLVING NKCCS | Universität Wien (AT) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163406-A1 | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs | KCNC1, SLC6A1, KCNJ11 | CA2 559/4885KDM4E 4012/4885USP2 4682/4885 |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | SLC9A1, SLC9A3, SLC5A1 | CA2 393/4885KDM4E 3838/4885USP2 3125/4885 |
| US-20260132103-A1 | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs | CLIC1, SLC6A1, KCNC1 | CA2 349/4885KDM4E 4138/4885USP2 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.